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Do New Brooms Sweep Clean?*Gregor Andelﬁnger, MDSEE PAGE 2498T he familial reverberation of heart diseasehas long captured the curiosity of clinicians.Interestingly, the observation that some
“morbid predisposition” is at the heart of the problem
in some families was actually made before Mendel’s
laws were known (1). Indeed, a precise genotype-
phenotype prediction of several rare syndromes that
are now well-known clinical entities—such as Holt-
Oram or Char syndromes—predates the arrival of
modern genetic technologies. Over the years, such
cases, in particular those with a familial basis, were
instrumental for 2 reasons: 1) for epidemiological in-
vestigations, they offered a means to estimate the
burden of disease attributable to genetic factors;
and 2) with the advent of more sophisticated genetic
tools, they provided a gateway to dissect the molecu-
lar basis of congenital heart disease (CHD).
Over the last decade, tremendous progress was
made in the area of genetic technologies. This in-
cludes genotyping, calling of copy number variants,
and next-generation sequencing (NGS) of the entire
coding part of the genome, called whole-exome
sequencing (WES). As a consequence, we better un-
derstand the genetic basis of numerous forms of
syndromic and nonsyndromic CHD (2), although the
proportion of cases explained by these studies re-
mains fairly small. For example, copy number vari-
ants are thought to explain 5% to 20% of selected
CHD, and WES studies implicate de novo mutations in
10% of sporadic severe cases (3–5).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Department of Pediatrics, Section of Cardiovascular Genetics,
Centre Hospitalier Universitaire Sainte Justine, Université de Montréal,
Montréal, Quebec, Canada. Dr. Andelﬁnger has reported that he has no
relationships relevant to the contents of this paper to disclose.In this issue of the Journal, Blue et al. (6) report the
results of screening a targeted panel of candidate
genes in a cohort of 16 families with a strong history
of CHD. The 57 genes of this panel were selected due
to their known involvement in human CHD or on the
basis of suggestive evidence from mouse studies. The
investigators compared these sequencing results to
those from 15 healthy control subjects as well as data
from the 1,000 Genomes Project (which is sequencing
the genomes of a multitude of people to develop a
comprehensive resource of human genetic variation)
and the ESP (Exome Sequencing Project) of the Na-
tional Heart, Blood, and Lung Institute, totaling more
than 6,000 control subjects. Variants identiﬁed as
damaging that also segregated with disease in indi-
vidual families were considered to be disease causing.
The investigators thus identiﬁed a pathogenic variant
in 5 of 16 (31%) of the families studied, at the same
time identifying a possible syndromic cause in 3 of
these 5 families on the basis of the genes identiﬁed.
Additionally, they found variants of unknown sig-
niﬁcance in 25% of the families studied, as well as an
excess of several types of rare genetic variation in the
familial CHD cohort versus control subjects.Although some ﬁndings of this study must be
interpreted cautiously, there are several grains of
truth for the pediatric and adult congenital cardiolo-
gist here, as well as questions that will take center
stage in the ﬁeld throughout the coming years. First,
and most importantly: how many cases were really
resolved using this approach? One could argue that in
hindsight, the results in several of the families who
received a deﬁnitive genetic diagnosis on the basis of
this study may have been predicted via clinical ex-
amination alone. This includes the family exhibiting a
TFABP2 mutation (Char syndrome), the 2 families
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2508with TBX5 mutations (Holt-Oram syndrome), and the
family with an ELN mutation (supravalvular aortic
stenosis). However, in reality, many of these families
present minimal clinical phenotypes, exhibit
decreased penetrance, or variable phenotypes. These
commonly observed phenomena, which hamper rapid
and easy phenotype recognition, were also present in
this study, corresponding to a clinical reality that can
be more easily resolved now using molecular di-
agnostics. To do this will require careful, step-by-step
correlation of genotypes with phenotypes; two pro-
cesses that contrast starkly at the level of throughput
given that NGS technologies generate lists of putative
variants of unprecedented scale, whereas phenotyp-
ing continues to be a more time-consuming task.
At the same time, we have to keep in mind that only
a small minority of CHD follows clear Mendelian
transmission patterns, and that the fraction of disease
explained in this study shrinks further if the denom-
inator becomes the entire pediatric cardiac patient
population. Extrapolating from other NGS studies in
complex disease traits, we can anticipate that WES
alone will not fully determine the causes of several
forms of CHD, at least not with the prevailing analysis
paradigm that WES will always detect causal coding
variants. As a case in point, applying WES to a multi-
plex family with bicuspid aortic valve and other car-
diovascular malformations failed to identify a single
strong coding variant, despite a family structure
similar to the many families that have greatly facili-
tated deciphering the Mendelian basis of disease with
NGS technologies over the last 4 years (7). Noncoding
variants and oligogenic inheritance likely contribute
to those cases that are not readily explained by rare
genetic variants predicted to have strong effects. The
major challenge here will be to provide consistent,
standardized distinctions between benign variants
and causal mutations, and to develop these ap-
proaches into truly personalized tools that ideally
solve the vast majority of cases at genetic level: only
pathogenic variants will be useful variants.
From a technical standpoint, WES has already su-
perseded targeted gene panels and affords an unbi-
ased, genome-wide interrogation of coding variants.
However, this technology’s obvious advantages
come at a considerable expense at the analytical
level. WES automatically generates many incidental
ﬁndings; results in the clinical setting are easier to
interpret if a clear genetic model can be applied for
analysis. Also, WES is inferior to targeted gene
panels in terms of depth of coverage, because NGS
technologies require that multiple sequencing reads
overlap to provide greater conﬁdence of genotype
calls. Therefore, WES is currently recommended onlyas a follow-up when other investigations, including
targeted gene panels, fail to yield results. While
these technologies mature, studies like the one by
Blue et al. (6) are important to establish which types
of CHD can be explained by speciﬁc gene sets in
deﬁned clinical settings. Further development of
content, yield, and indications for tractable CHD
gene sets will require larger studies, ideally with
biological samples and medical history for family
members. When such information is available, ge-
netic models can be applied to facilitate interpreta-
tion of sequencing results: for instance, for sporadic,
severe phenotypes, analysis would be performed
assuming a de novo mutation, whereas studies like
the one by Blue et al. (6) would require cosegregation
of alleles with the phenotype (4).
The current study also raises the question whether
pediatric cardiology has the resources to deal with the
progress made in the genomics arena. Historically, our
ﬁeld has progressed more through a mechanical than a
mechanistic paradigm. This study is 1 of several that
now shift this stance and point toward the need of
properly trained pediatric cardiologists with a knowl-
edge base and procedural competence commensurate
with the possibilities the new technologies afford.
Genomic tools and insights are evolving rapidly and
fellowship programs and continuing medical educa-
tion must adapt quickly to these realities. Beyond the
training of candidates for investigative careers, core
curricula must change rapidly to keep pace with the
progress in the genomics arena and to fulﬁll its prom-
ises of improved patient care.
Finally, will results from this study change patient
management? For several patients in the study pre-
sented here, the results are already actionable. Mu-
tations in TBX5 may inﬂuence the lifetime risk for
atrioventricular block, and carrier status for a highly
penetrant causal mutation offers insights into recur-
rence risk. Related examples are diagnosis and care
for patients and families with heritable arrhythmias
and cardiomyopathies, which have undergone sig-
niﬁcant changes with the advent of genetic diagnoses,
or Marfan syndrome, where novel therapeutic targets
have emanated from mechanistic insight (8). As a
“new broom,” NGS is rapidly becoming a very impor-
tant tool to uncover those leads that hold the potential
to improve patient care.
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